Literature DB >> 8689625

Modification of mitomycin C-induced clastogenicity by Terminalia catappa L. in vitro and in vivo.

T Y Liu1, L K Ho, Y C Tsai, S H Chiang, T W Chao, J H Li, C W Chi.   

Abstract

The water extract of the leaves of Terminalia catappa L. was tested for inhibition of mitomycin C-induced micronuclei in CHO-K1 cells. The simultaneous and pre-treatment of CHO-K1 cells with T. catappa extract (75 and 150 micrograms/ml) significantly (P < 0.05) suppressed mitomycin C-induced micronuclei. Furthermore, gastric intubation of T. catappa extract (4.8 and 24 mg/animal per day) to male ICR mice for 8 days significantly (P < 0.01) reduced mitomycin C-induced micronuclei in peripheral blood. In addition, T. catappa dose dependently inhibited lipid peroxidation in vitro and TPA-induced hydrogen peroxide formation in human mononuclear leukocytes. The anticlastogenic effects of T. catappa in vitro and in vivo may be attributed to its antioxidative potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8689625     DOI: 10.1016/0304-3835(96)04269-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

Review 1.  An updated review of Terminalia catappa.

Authors:  Arumugam Vijaya Anand; Natarajan Divya; Pannerselvam Punniya Kotti
Journal:  Pharmacogn Rev       Date:  2015 Jul-Dec

2.  Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase-9 by Modulating NF-κB and AP-1 Activity.

Authors:  Chao-Bin Yeh; Ming-Ju Hsieh; Yih-Shou Hsieh; Ming-Hsien Chien; Pen-Yuan Lin; Hui-Ling Chiou; Shun-Fa Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-08       Impact factor: 2.629

3.  Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.

Authors:  Chao-Bin Yeh; Yung-Luen Yu; Chiao-Wen Lin; Hui-Ling Chiou; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  BMC Complement Altern Med       Date:  2014-04-30       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.